Pfizer's Legal Battle: Clash Over Metsera Acquisition

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk and anti-competitive tactics. Metsera, a developing drugmaker, caught interest for its potential obesity and diabetes treatments, setting the stage for a high-stakes corporate clash.

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, following Novo's announcement of a $9 billion acquisition bid for Metsera, which exceeded Pfizer's $5 billion offer.

Despite Novo's higher bid, Pfizer argues the offer is overshadowed by significant regulatory risks that could hinder the deal's completion.

The legal dispute underscores competition for access to promising treatments in obesity and diabetes, potentially revolutionizing these lucrative health areas.